JW Therapeutics filed with Hong Kong Trading and Settlement Limited on February 5, 2024 with Hong Kong Trading and Settlement Holdings Limited, covering the situation as of January 31, 2024. The report showed that the company's regulary/registered share capital remained unchanged at $50,000 and the number of ordinary shares remained at 5,000,000,000 shares. In terms of stock options, under the incentive plans adopted in 2019 and 2020, some share options were exercised this month, leading to the issuance of new shares. The number of stock options outstanding at the end of the month was 25,192,815 shares, and the total number of ordinary shares increased to 295,620 shares this month. The Company confirms that all securities issuance has been approved by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.

JW Therapeutics filed with Hong Kong Trading and Settlement Limited on February 5, 2024 with Hong Kong Trading and Settlement Holdings Limited, covering the situation as of January 31, 2024. The report showed that the company's regulary/registered share capital remained unchanged at $50,000 and the number of ordinary shares remained at 5,000,000,000 shares. In terms of stock options, under the incentive plans adopted in 2019 and 2020, some share options were exercised this month, leading to the issuance of new shares. The number of stock options outstanding at the end of the month was 25,192,815 shares, and the total number of ordinary shares increased to 295,620 shares this month. The Company confirms that all securities issuance has been approved by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.